Literature DB >> 22623374

Gaucher disease paradigm: from ERAD to comorbidity.

Inna Bendikov-Bar1, Mia Horowitz.   

Abstract

Mutations in the GBA gene, encoding the lysosomal acid beta-glucocerebrosidase (GCase), lead to deficient activity of the enzyme in the lysosomes, to glucosylceramide accumulation and to development of Gaucher disease (GD). More than 280 mutations in the GBA gene have been directly associated with GD. Mutant GCase variants present variable levels of endoplasmic reticulum (ER) retention, due to their inability to correctly fold, and undergo ER-associated degradation (ERAD) in the proteasomes. The degree of ER retention and proteasomal degradation is one of the factors that determine GD severity. In the present review, we discuss ERAD of mutant GCase variants and its possible consequences in GD patients and in carriers of GD mutations.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623374     DOI: 10.1002/humu.22124

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  20 in total

1.  Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation.

Authors:  Chunzhang Yang; Herui Wang; Dongwang Zhu; Christopher S Hong; Pauline Dmitriev; Chao Zhang; Yan Li; Barbara Ikejiri; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

2.  ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease.

Authors:  Yun Lei Tan; Joseph C Genereux; Sandra Pankow; Johannes M F G Aerts; John R Yates; Jeffery W Kelly
Journal:  Chem Biol       Date:  2014-08-14

3.  Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.

Authors:  Chunzhang Yang; Cody L Swallows; Chao Zhang; Jie Lu; Hongbin Xiao; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-18       Impact factor: 11.205

Review 4.  Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease.

Authors:  Caleb Pitcairn; Willayat Yousuf Wani; Joseph R Mazzulli
Journal:  Neurobiol Dis       Date:  2018-03-14       Impact factor: 5.996

Review 5.  Using pharmacological chaperones to restore proteostasis.

Authors:  Ya-Juan Wang; Xiao-Jing Di; Ting-Wei Mu
Journal:  Pharmacol Res       Date:  2014-04-18       Impact factor: 7.658

6.  Glucocerebrosidase and parkinsonism: lessons to learn.

Authors:  Ivanka Marković; Nikola Kresojević; Vladimir S Kostić
Journal:  J Neurol       Date:  2016-03-19       Impact factor: 4.849

Review 7.  Glucocerebrosidase is shaking up the synucleinopathies.

Authors:  Marina Siebert; Ellen Sidransky; Wendy Westbroek
Journal:  Brain       Date:  2014-02-14       Impact factor: 13.501

Review 8.  The Role of iPSC Modeling Toward Projection of Autophagy Pathway in Disease Pathogenesis: Leader or Follower.

Authors:  Mina Kolahdouzmohammadi; Mehdi Totonchi; Sara Pahlavan
Journal:  Stem Cell Rev Rep       Date:  2020-11-27       Impact factor: 5.739

Review 9.  Gaucher disease - more than just a rare lipid storage disease.

Authors:  Jaehyeok Roh; Subbaya Subramanian; Neal J Weinreb; Reena V Kartha
Journal:  J Mol Med (Berl)       Date:  2022-01-23       Impact factor: 4.599

10.  Functional analysis of 11 novel GBA alleles.

Authors:  Erika Malini; Serena Grossi; Marta Deganuto; Camillo Rosano; Rossella Parini; Silvia Dominisini; Roberta Cariati; Stefania Zampieri; Bruno Bembi; Mirella Filocamo; Andrea Dardis
Journal:  Eur J Hum Genet       Date:  2013-09-11       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.